BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8566091)

  • 1. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
    Tsou K; Patrick SL; Walker JM
    Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
    Stewart JL; McMahon LR
    J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
    González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
    Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the cannabinoid CB(1) receptor antagonist, SR141716A, after Delta(9)-tetrahydrocannabinol withdrawal.
    Beardsley PM; Martin BR
    Eur J Pharmacol; 2000 Jan; 387(1):47-53. PubMed ID: 10633159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
    Cook SA; Lowe JA; Martin BR
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
    Tanda G; Loddo P; Di Chiara G
    Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH; Sheikh SM; Loh HH; Martin BR
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
    Aceto MD; Scates SM; Lowe JA; Martin BR
    Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
    Lichtman AH; Fisher J; Martin BR
    Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum.
    Tzavara ET; Valjent E; Firmo C; Mas M; Beslot F; Defer N; Roques BP; Hanoune J; Maldonado R
    Eur J Neurosci; 2000 Mar; 12(3):1038-46. PubMed ID: 10762335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
    Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
    Aceto MD; Scates SM; Lowe JA; Martin BR
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1290-5. PubMed ID: 8819514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ; Crim JL; Darmani NA
    Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
    Dhawan K; Kumar S; Sharma A
    J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
    Trexler KR; Nass SR; Crowe MS; Gross JD; Jones MS; McKitrick AW; Siderovski DP; Kinsey SG
    Drug Alcohol Depend; 2018 Oct; 191():14-24. PubMed ID: 30071445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.
    Järbe TU; Lamb RJ; Liu Q; Makriyannis A
    Eur J Pharmacol; 2003 Apr; 466(1-2):121-7. PubMed ID: 12679148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.
    Darmani NA
    Pharmacol Biochem Behav; 2001; 69(1-2):239-49. PubMed ID: 11420092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
    Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
    J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
    Tai S; Nikas SP; Shukla VG; Vemuri K; Makriyannis A; Järbe TU
    Psychopharmacology (Berl); 2015 Aug; 232(15):2751-61. PubMed ID: 25772338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonist-elicited cannabis withdrawal in humans.
    Gorelick DA; Goodwin RS; Schwilke E; Schwope DM; Darwin WD; Kelly DL; McMahon RP; Liu F; Ortemann-Renon C; Bonnet D; Huestis MA
    J Clin Psychopharmacol; 2011 Oct; 31(5):603-12. PubMed ID: 21869692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.